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Open access undBackground: The RADAR trial determines whether adjuvant androgen suppression, bisphosphonates and
radiation dose escalation for localised prostate cancer (PC) may improve oncologic outcomes. This study
examines whether these measures increase rectal and urinary dysfunction and are secondary trial end-
points.
Methods: Using a 2  2 factorial trial design men with locally advanced PC were randomly allocated
6 months i.m. leuprorelin prior to radiotherapy either alone or followed by 12 months i.m. leuprorelin.
These two groups received 18 months i.v. zoledronic acid (Z) commencing at randomisation or no further
treatment. Radiotherapy dose was escalated in a regulated way using external beam techniques (EBRT) or
by a high dose rate brachytherapy (HDRB) boost. Prevalence rates of rectal and urinary dysfunctional
symptoms were compared at baseline, the end of RT, 18 and 36 months according to treatment arm, dose
and technique using multiple regression models.
Results: Between 2003 and 2007, 1071 men were randomly allocated and eligible for inclusion in this
study. No persistent differences in rectal or urinary dysfunction were attributable to treatment arm or
to increasing EBRT dose. However following HDRB statistical increases (p < 0.001) in urinary dysfunction
were measured using the EORTC PR25 instrument at 18 and 36 months.
Conclusion: Adjuvant androgen suppression, bisphosphonates and increasing EBRT dose did not increase
rectal or urinary dysfunction in this trial. However dose escalation using HDRB increased urinary
dysfunction.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 105 (2012) 184–192Several trials have shown that androgen suppression therapy
(AS) improves outcomes after radiotherapy (RT) for prostate cancer
[1–6]. Two or more years of AS have been shown to be more efﬁ-
cacious than six months or less [7,8], however longer durations
of AS have also been shown to cause more long term morbidity
[9–13]. These considerations led us to take a conservative approach
to the use of long term AS in further trials after the TROG 96.01
trial, which had demonstrated the advantage of adding six months
neo-adjuvant AS to RT [14]. In its successor, the TROG 03.04 RADARith the National Institutes of
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al ID. 03/06/11/3.02).
castle, Locked Bag 1, Hunter
W. Denham).
er CC BY-NC-ND license.trial, we therefore investigated whether an additional 12 months
of AS following 6 months neo-adjuvant AS (i.e. total 18 months
AS) and RT would achieve outcomes that 2 or more years adjuvant
AS can produce, without long term ill effects. As the nitrogen bis-
phosphonates had shown in vitro efﬁcacy in prostate cancer cell
lines [15–17] and had reduced skeletal related events in an ad-
vanced hormone resistant metastatic prostate cancer trial [18]
we also used the RADAR trial to test the effect of 18 months of
zoledronic acid (Z) (4 mg i.v. every 3 months). We hypothesised
that Z might lower the rate of bone metastases as well as reduce
AS induced osteopaenia. The trial’s oncologic outcomes, including
main endpoint prostate cancer speciﬁc mortality, will be reported
in 2014 when its power will exceed 80% to discriminate important
treatment arm effects.
The major limitation of the TROG 96.01 trial was the now out-
dated RT technique and prescribed dose employed in that study.
We therefore took advantage of the better RT delivery systems
available in Australia and New Zealand in 2003 to build a
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using external beams alone or followed by a high dose rate
brachytherapy (HDRB) boost [19,20]. Since secondary trial end-
points included rectal and urinary morbidity that were speciﬁed
in the protocol to be analysed after 5 years minimum follow up
from randomisation (i.e. in 2012), the present study aimed to
determine whether the study drugs and/or the higher radiation
doses used in the dose escalation programme inﬂuenced these
endpoints. It also addresses the utility of dose–volume histogram
data as a predictor of different symptoms resulting from rectal
dysfunction.
Androgen suppression therapy is known to reduce bone mineral
density and increase fracture rates. These secondary trial end-
points may be prevented by the adjuvant use of zoledronic acid
and will be reported in a specialised journal [21]. Other well
known consequences of AS, such as sexual dysfunction and other
related effects including ﬂushes, gynaecomastia, weight gain and
anaemia, can adversely inﬂuence quality of life and this group of
secondary trial endpoints are also reported elsewhere [22].Methods
Patients and treatment
Men with histologically conﬁrmed adenocarcinoma of the pros-
tate without lymph node or systemic metastases with T stage 2b
and above or T stage 2a primary tumours of Gleason scoreP7 his-
tology and baseline PSA levels P10 ng/mL immediately prior to
randomisation were eligible to participate after providing their
written informed consent. After stratiﬁcation by treatment centre,
baseline PSA level (10/10–20/>20), Gleason score (66/P7), and T
stage (T2/T3,4), random allocation using the minimisation tech-
nique occurred at the Central Ofﬁce in Newcastle, Australia to
one of four treatment arms. Additional stratiﬁcation by HDR brach-
ytherapy boost centre is outlined below. All men received
6 months of leuprorelin (22.5 mg i.m. 3 monthly) commencing at
randomisation, 5 months before RT to the prostate and seminal
vesicles (but not to pelvic lymph nodes). Men in the control arm re-
ceived no further treatment (i.e. short term AS [STAS]). Men in the
other androgen suppression only treatment arm received an addi-
tional 12 months of leuprorelin (22.5 mg i.m. 3 monthly) (i.e. inter-
mediate term AS [ITAS]). Men allocated to the two bisphosphonate
treatment arms received zoledronic acid 4 mg i.v. every 3 months
for 18 months starting at randomisation with 6 months leuprorelin
(22.5 mg i.m.) starting 5 months before RT (STAS + Z) or the same
AS plus RT followed by 12 months leuprorelin (22.5 mg i.m. 3
monthly) (ITAS + Z). The trial’s main endpoint is prostate cancer
speciﬁc mortality (PCSM) and will be reported alongside other
oncological endpoints in 2014. In this report we describe the ef-
fects of the study drugs and radiation dose escalation on rectal
and urinary dysfunctional symptoms. These are protocol speciﬁed
secondary trial endpoints scheduled for analysis in 2012 after
5 years minimum follow up.
In the RADAR trial a regulated radiation dose escalation pro-
gramme was achieved by requiring participating centres to select
their preferred dosing options from a pre-determined range of
doses and techniques. The dosing options were 66, 70 and 74 Gy
to the ICRU point using external beam alone (EBRT only) and
46 Gy to the ICRU point using external beam followed by a high
dose rate brachytherapy (HDRB) boost dose of 19.5 Gy using three
fractions of 6.5 Gy. Before enrolling subjects or selecting dose and
technique each centre had to demonstrate that it could meet the
pre-determined accuracy of dose delivery criteria speciﬁed in the
trial protocol [20]. These criteria were dose dependent in strin-
gency and are described in more detail in the Web appendix. Hav-
ing selected a speciﬁc dose level, each centre continued to use thisdose from thereon. Dose escalation to the next dose level was per-
mitted at a treatment centre if it could meet the more stringent
treatment accuracy criteria speciﬁed for that dose level. Because
only four centres had HDRB equipment and were already selec-
tively using it as a means to escalate dose in the primary tumour
(i.e. as a ‘‘boost’’ dose) in men with stage T3 tumours, the use of
HDRB at these centres was a separate stratiﬁcation factor at ran-
domisation. It must be stressed that assignment to dose and tech-
nique was not a random process in the trial, however the
stratiﬁcation scheme employed ensured that radiation dose and
technique used were balanced evenly across trial arms and that
baseline prognostic factors (T stage, Gleason grade grouping and
initial PSA) were also evenly balanced in each trial arm. Consis-
tency in EBRT dose delivery was assessed via dosimetric audit of
participating centres [23–25] and adherence to trial planning pro-
tocol via expert review of each participant’s treatment plan at the
technical review centre in Perth using the SWAN system [26].
Full details of the derivation of radiation target volumes, dose
volume histogram constraints and set up accuracy requirements
are provided in the relevant portions of the RADAR trial protocol
which are reproduced in the Web Appendix.
Brieﬂy the GTV needed to encompass the prostate only in sub-
jects with T stage <3b, Gleason score <8 and iPSA <20 tumours. The
seminal vesicles needed to be included in the GTV of subjects with
tumours exceeding one or more of these criteria. In centres not
equipped to treat conformally one PTV (i.e. without size reduction)
required treatment with minimum margins built around the GTV
of 10 mm, excepting posteriorly where the margin could be as
small as 5 mm. In centres equipped to treat conformally, two PTVs
could be treated if the treating investigator considered necessary
i.e. using a PTV 1 to between 46 and 60 Gy, followed by a size
reduction to PTV 2 where the remaining dose (to 70 or 74 Gy)
would be delivered. Margins built around GTV 1 to achieve PTV 1
were set at 10–15 mm, except posteriorly where they were 5–
10 mm. Margins around GTV 2 to achieve PTV 2 were set at
<10 mm, except posteriorly where they were 65 mm. Rectal dose
constraints mandated that no more than 30% of the rectal volume
should receive 70 Gy, and no more than 30% of the femoral heads
should receive 60 Gy. In subjects receiving a HDRB boost the ante-
rior rectal wall was required to receive no more than 70% of the
reference dose and the prostatic urethra no more than 120%. The
use of multiple co-planar ﬁelds was allowable either with the sub-
ject prone or supine. Beam energies needed to be 6 MV or greater.Follow up
After treatment, all patients were routinely followed up in clinic
every 3 months for 18 months, then 6 monthly up to 5 years post
randomisation and then annually for a further 5 years. At each visit
new PSA levels were documented, clinician assessed outcomes
were collected and clinical examinations including digital rectal
examination were performed. If signs of PSA or clinical progression
had taken place treating clinicians were encouraged to follow a set
of relapse diagnosis guidelines. These recommended delay of sec-
ondary therapeutic intervention (STI) until metastatic (distant)
progression was diagnosed. Protocol speciﬁed laboratory investi-
gations included serum haemoglobin and PSA levels before all
clinic visits, testosterone, calcium and phosphate levels at speciﬁed
time points during and after AS, and renal function studies
throughout treatment and at speciﬁed time points afterwards.
Patient reported outcomes were captured using the EORTC QLQ
C-30 and PR25 questionnaires, the International Prostate Symptom
Score (IPSS) for urinary function and pharmaceutical intervention
(PI) questionnaire for AS and bisphosphonate side effects at base-
line, 3 months, end of RT, 12 months, 18 months, 24 months,
36 months, 60 months and then yearly.
186 Rectal and urinary dysfunctionEndpoints
The severity of symptoms and signs of rectal and urinary func-
tion recorded on the clinician assessment form and the patient re-
ported outcome questionnaires form the basis of the endpoints
selected for presentation in this report.
Dysfunctional rectal symptoms selected as endpoints and ana-
lysed were: faecal incontinence (based on EORTC QLQ-PR25 ques-
tion 11), rectal bleeding, urgency and tenesmus, and frequency of
bowel action (according to Lent Soma Scales) [27]. Clinician as-
sessed Common Toxicity Criteria (CTC version 2) score was also se-
lected as an endpoint and analysed. As symptom severity and CTC
scores seldom reached moderate or severe levels, each endpoint
was dichotomised at the minimum severity level or greater. At
each time point patients were therefore classiﬁed as having absent
symptoms (grade 0) or mild to greater symptom severities
(gradeP 1), and prevalence estimates at selected time points were
determined on this basis. Dysfunctional urinary descriptions se-
lected as endpoints and analysed were the International Prostate
Symptom Score (IPSS), the EORTC PR25 urinary function domain,
strength of urinary stream (IPSS question 5) and dysuria (according
to Lent Soma Scale). Prevalence rates at selected time points were
based on mean IPSS, PR25 urinary domain score, weak urinary
stream scoreP4 (‘‘more than half of the time’’ or ’’almost always’’),
and dysuria grade P1 (ranging from ‘‘occasional and mild’’ to
‘‘refractory and excruciating’’).
For rectal dose volume histogram purposes, the entire rectum
from anal verge to recto-sigmoid was outlined and used in calcula-
tion. All dosimetric data were sent to Perth for analysis using the
SWAN software. Dose–volume data for the rectum were automat-
ically generated from archived digital treatment planning data
using the SWAN system [26]. To ensure consistency across pa-
tients, dose–volume data submitted with treatment plans were
not used, and instead dose–volume data were independently recal-
culated in SWAN [28].Analyses
In an earlier report we found that Kaplan–Meier time to procto-
pathic event probabilities grossly overestimated the occurrence of
proctopathy in the TROG 96.01 trial [29] because of ﬂuctuations in
the symptom burden. Prevalence rates were found to provide a
more realistic estimate of the burden of proctopathy in a particular
study group at any given time point. Comparison of morbidity
rates in treatment groups based on trial arm, radiation dose and
technique was therefore achieved in this study by comparing prev-
alence of individual endpoints at speciﬁc time points; baseline, end
of RT, and at 18 and 36 months after randomisation. Univariable
comparison of prevalence rates was done using Chi square tests
and multi-variable comparisons by multiple logistic regression
modelling for dichotomised endpoint variables and multiple linear
regression for continuous endpoint variables such as IPSS and PR25
urinary domain score. In rectal symptom modelling adjusting
factors were age at randomisation (<63/63–68.99/69–72.99/
P73 years), the presence of pre-existing colo-rectal disorders
(yes/no), hypertension (yes/no), diabetes (yes/no), smoking habit
(no history/previous smoker/current smoker) and the use of statins
and/or ACE inhibitors (yes/no). In the two models addressing treat-
ment arm effects, radiation dose and technique (high dose rate
brachytherapy boost [HDRB]/66/70/74 Gy) (Model 1) and boost
technique (HDRB/EBRT only (Model 2) were additional co-vari-
ables. However in a third model addressing the prognostic impor-
tance of the percentage of rectal volume encompassed by the 60 Gy
isodose line or region, percentage of rectum receiving >60 Gy (as a
continuous variable) was an additional co-variable and the model
was restricted to men receiving EBRT only because reliable com-posite dose volume histograms were not available in men receiving
HDRB boosts. In urinary symptom models multiple linear regres-
sion models were used to evaluate IPSS and PR25 scores. Adjusting
factors were those used in the two non-DVH rectal symptom mod-
els, but also included alcohol consumption (none/occasional/
regular).
A two-sided signiﬁcance level of <0.01 was regarded as signiﬁ-
cant because multiple tests were done. All analyses were per-
formed using Stata version 11.2.Results
Between October 2003 and August 2007, 1071 eligible subjects
were randomly allocated to the RADAR trial’s four trial arms. Fur-
ther demographic information are provided in Table 1. Baseline
characteristics and radiotherapy dose/technique were balanced
across trial arms, but higher T stage and Gleason score tumours
were present in subjects receiving the HDRB boost. Questionnaire
completion rates were high. After taking into account withdrawals,
losses to follow up and deaths, complete rectal dysfunction data-
sets were available for analysis in 94.7% of men at baseline,
93.9% at the end of radiotherapy, 94.9% at 18 months and 97.9%
at 36 months. The corresponding rates for complete urinary dys-
function datasets were 93.2% at baseline, 91.6% at the end of radio-
therapy, 89.7% at 18 months and 92.2% at 36 months. Grade 2, 3
scores were uncommon. At the end of RT only 76 subjects (7.2%)
had grade 2 scores and 1 subject had grade 3. At 18 and 36 months
26 (2.6%) and 15 (1.7%) subjects respectively had grade 2 scores,
and 1 and 3 subjects respectively had grade 3 scores. Only 1 subject
had a grade 4 score (at 24 months).
The use of adjuvant AS only (ITAS arm) and Z (STAS + Z and
ITAS + Z arms) did not alter the prevalence rates of any proctopath-
ic symptom or the clinician assigned CTC score produced by the
control arm (STAS) at any time point as shown in Fig. 1 and Web
Appendix Table 1. The percentages of men who experienced CTC
proctopathy at Grade P1 ranged between 37.3% and 42.2% across
the four treatment arms at the end of radiotherapy and between
15.4% and 18.1% at 36 months.
There were no statistical differences in proctopathic symptoms
or assigned CTC score at any time point in men assigned 66, 70 or
74 Gy without HDRB boost dose as shown in Fig. 2 and Table 2. No
prescribed dose effect relationship was therefore discernible. How-
ever the percentage of rectal volume treated to doses exceeding
60 Gy was a predictor of some dysfunctional symptoms, but not
in a consistent way. For example this parameter was a signiﬁcant
predictor of urgency and tenesmus and bowel frequency at end
of RT, but not at later time points. On the other hand, it was not
a signiﬁcant predictor of rectal bleeding and CTC score at the end
of RT, but was at 36 months. A consistent cutpoint, reliably distin-
guishing men with high symptom levels from those with lower
symptom levels, was not identiﬁed.
Regardless of the symptom levels reported and CTC score as-
signed at the end of RT, men receiving HDRB boost were less likely
to experience any proctopathic symptoms or receive CTC scores >0
at 18 and 36 months than men treated without HDRB boosts, but
the differences were not consistent and did not reach signiﬁcance.
At the end of RT, dysfunctional symptom levels and CTC scores ap-
peared to be signiﬁcantly lower in men receiving HDRB boosts.
However this ﬁnding was misleading. In 80 (35.9%) of 223 men
receiving HDRB boost within the time frame speciﬁed in the proto-
col (i.e. 665 days) and who had completed their assessments expe-
ditiously, proctopathic symptoms and CTC scores >0 occurred just
as frequently as in men treated without HDRB boost. However in
the 143 (64.1%) of 223 men who either had their end of RT assess-
ment delayed for logistical reasons or experienced delays
Table 1
Characteristics of the 1071 subjects’ ages, tumours and radiation doses.
STAS STAS + Z ITAS ITAS + Z HDRB 66 Gy 70GY 74GY Total
Randomised 268 268 268 267 237 125 427 262 1071
Age
Median 69.3 69.1 68.6 68.2 68.0 69.5 69.9 66.4
Interquartile range 63.9–73.3 63.8–73.3 63.3–73.2 63.6–72.3 66.1–72.8 64.1–73.2 64.6–74.1 60.6–71.4
T stage
T2 170 (63.4) 171 (63.8) 170 (63.4) 169 (63.3) 85 (35.9) 94 (75.2) 311 (72.8) 179 (68.3) 680 (63.5)
T3,4 98 (36.6) 97 (36.2) 98 (36.6) 98 (36.7) 152 (64.1) 31 (24.8) 116 (83) 83 (31.7) 391 (36.5)
Gleason score
<7 26 (9.7) 25 (9.3) 25 (9.3) 25 (9.4) 4 (1.7) 18 (14.4) 48 (11.2) 29 (11.1) 101 (9.4)
=7 155 (57.8) 155 (57.8) 138 (51.5) 151 (56.6) 112 (47.3) 73 (58.4) 261 (61.1) 143 (54.6) 599 (55.9)
>7 87 (32.5) 88 (32.8) 105 (39.2) 91 (34.1) 121 (51.1) 34 (27.4) 118 (27.6) 90 (34.4) 371 (34.6)
iPSA group
<10 74 (27.6) 74 (27.6) 72 (26.9) 73 (27.3) 60 (25.3) 38 (30.4) 120 (28.1) 68 (26.0) 293 (27.4)
10–<20 107 (39.9) 107 (39.9) 104 (38.8) 107 (40.1) 92 (38.8) 52 (41.6) 179 (41.9) 97 (37.0) 425 (39.7)
P20 87 (32.5) 87 (32.5) 92 (34.3) 87 (32.6) 85 (35.9) 35 (28.0) 128 (30.0) 97 (37.0) 353 (33.0)
RT dose
HDRB 57 (21.3) 57 (21.3) 61 (22.8) 62 (23.2) NA NA NA NA 237 (22.1)
66 Gy 30 (11.2) 30 (11.2) 32 (11.9) 33 (12.6) NA NA NA NA 125 (11.7)
70 Gy 111 (41.4) 108 (40.3) 106 (39.6) 102 (38.2) NA NA NA NA 427 (39.9)
74 Gy 68 (25.4) 65 (24.3) 64 (23.9) 65 (24.3) NA NA NA NA 262 (24.5)
Not given/per protocol 2 (0.7) 8 (3.0) 4 (1.5) 6 (2.2) NA NA NA NA 20 (1.9)
Bolded values are considered statistically signiﬁcant.
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Fig. 1. Rectal and urinary dysfunctional symptoms at various time points between randomisation and 36 months according to assigned trial arm. Signiﬁcant differences
(p < 0.01) are indicated by stars at the relevant time point.
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188 Rectal and urinary dysfunction(>65 days) in their HDRB boosts, rectal bleeding, urgency and
tenesmus symptoms and CTC scores >0 were signiﬁcantly less fre-
quent. Reductions in early symptomatology in these men did not
translate into reductions at later time points. At 18 and 36 months,
similar proportions of men experienced dysfunctional symptoms
whether their HDRB was delayed or not, as shown in Web appen-
dix Fig. 1a. Therefore although it cannot be concluded that use of
the HDRB boost lead to a reduction in dysfunctional symptoms,
it can be concluded that its use did not increase rectal symptoms
or CTC score.
There was no apparent inﬂuence of hypertension (pre-existing
or current), diabetes, smoking, and statin and/or ACE inhibitor
use on development of rectal symptoms. Pre-existing colo-rectal
disorders were predictive of CTC score at baseline (i.e. prior to
any protocol treatment) but not at time points during and after
treatment. An inconsistent but common ﬁnding that merits further
investigation is an inverse relationship between the symptoms re-
ported and the assigned CTC scores at all time points (including
baseline) with advancing age.
Except for increased IPSS and PR25 urinary domain scores in the
ITAS + Z arm at the 18 month time point which did not persist at
later time points, dysfunctional urinary symptoms were very sim-
ilar in all four treatment arms (Figure 1 and Table 3). Mean IPSS
scores in the four arms ranged between 14.4 and 14.8 at the end
of RT, and between 6.0 and 7.2 at 36 months. The non-statisticalimprovement at 18 months was attributable to an improvement
in urinary stream strength over the study period (Table 3 and
Web Appendix Fig. 2).
In men receiving external beam therapy without a HDRB boost,
no prescribed dose effect relationship was discernible for any of
the urinary dysfunction symptoms. Symptom levels were similar
at all time points at all three (66, 70 and 74 Gy) dose levels
(Fig. 2). The relative magnitudes of the effects of HDRB boost on
dysfunctional urinary symptoms at different time points are de-
picted in Fig. 2.
At 18 months, symptoms of urinary dysfunction were signiﬁ-
cantly more common in men treated with the HDRB boost (mean
IPSS: 9.5 and dysuria [OR: 6.4]) than in men treated without it
(mean IPSS: 6.8, p < 0.001 and dysuria [OR: 1] p < 0.001). However
beyond 36 months, this increase remained statistically signiﬁcant
for the PR25 urinary domain and dysuria scores only (Table 3).
The maximum difference in PR25 scores between the groups was
7.1 at 18 months, which falls below the difference of 10 that is con-
sidered ‘‘clinically relevant’’. However the proportion of men who
received HDRB and experienced changes of 10 or more for the
worse from baseline to 18 months was 36.1% compared with
17.25% for men receiving EBRT alone (p < 0.001). Moreover the pro-
portions of men that experienced improvements of 10 or more
were 8.3% and 15.7% respectively, indicating a highly signiﬁcant
and clinically relevant difference between the groups.
Table 2
Dysfunctional rectal symptoms: comparisons of the trial arms, radiation doses and techniques.
Timing Modela Variable Endpointb
CTC Bleeding Urgency Frequency Incontinence
OR p-Value OR p-Value OR p-Value OR p-Value OR p-Value
End RT Model 1 STAS 1 – 1 – 1 – 1 – 1 –
STAS + Z 0.97 0.870 1.11 0.643 1.31 0.155 0.67 0.030 1.08 0.725
ITAS 1.03 0.860 0.88 0.583 1.09 0.655 0.74 0.113 0.92 0.691
ITAS + Z 1.20 0.345 1.00 0.993 1.13 0.528 0.93 0.684 1.00 0.994
HDRB 1 – 1 – 1 – 1 – 1 –
66 Gy 4.91 <0.001 3.17 <0.001 2.48 <0.001 1.81 0.011 1.10 0.715
70 Gy 4.43 <0.001 3.70 <0.001 3.14 <0.001 2.54 <0.001 1.00 0.981
74 Gy 3.74 <0.001 3.38 <0.001 2.58 <0.001 1.79 0.002 1.16 0.498
Model 2 EBRT 1 – 1 – 1 – 1 – 1 –
HDRB 0.23 <0.001 0.28 <0.001 0.35 <0.001 0.46 <0.001 0.94 0.739
Model 3 % rectal volume > 60 Gyc 1.01 0.041 1.01 0.367 1.02 0.001 1.03 <0.001 1.02 0.012
18 months Model 1 STAS 1 – 1 – 1 – 1 – 1 –
STAS + Z 1.09 0.720 1.63 0.046 0.79 0.272 0.79 0.272 0.94 0.800
ITAS 0.96 0.866 1.52 0.090 1.08 0.695 1.08 0.695 1.22 0.374
ITAS + Z 0.77 0.291 1.25 0.379 0.79 0.265 0.79 0.265 1.39 0.142
HDRB 1 – 1 – 1 – 1 – 1 –
66 Gy 1.56 0.121 1.54 0.146 0.92 0.766 1.13 0.540 1.52 0.127
70 Gy 0.93 0.734 1.14 0.568 1.15 0.456 1.09 0.650 1.42 0.102
74 Gy 1.25 0.357 1.53 0.080 0.82 0.350 1.17 0.426 1.03 0.902
Model 2 EBRT 1 – 1 – 1 – 1 – 1 –
HDRB 0.90 0.592 0.76 0.178 1.00 0.990 1.28 0.115 0.77 0.176
Model 3 % rectal volume > 60 Gyc 1.02 0.026 1.02 0.005 1.01 0.048 1.00 0.969 1.02 0.019
36 months Model 1 STAS 1 – 1 – 1 – 1 – 1 –
STAS + Z 1.25 0.400 1.04 0.875 1.09 0.705 1.02 0.922 1.24 0.416
ITAS 1.13 0.640 0.84 0.475 0.98 0.935 1.16 0.475 1.39 0.190
ITAS + Z 1.21 0.455 0.97 0.898 1.10 0.676 0.98 0.931 1.20 0.475
HDRB 1 – 1 – 1 – 1 – 1 –
66 Gy 1.68 0.105 1.87 0.041 1.86 0.043 0.76 0.309 1.97 0.024
70 Gy 1.23 0.417 1.94 0.005 2.73 <0.001 1.59 0.015 1.34 0.231
74 Gy 1.85 0.022 1.50 0.126 1.88 0.015 0.88 0.562 1.24 0.420
Model 2 EBRT 1 – 1 – 1 – 1 – 1 –
HDRB 0.67 0.085 0.56 0.009 0.44 <0.001 0.84 0.334 0.71 0.126
Model 3 % rectal volume > 60Gyc 1.03 0.002 1.03 <0.001 1.01 0.093 1.01 0.059 1.01 0.093
Abbreviations: CTC, Common Toxicity Criteria (version 2); OR, odds ratio; IPSS, International Prostate Symptom Score; STAS, short term (6 months) androgen suppression;
ITAS, intermediate term (18 months) androgen suppression; Z, zoledronic acid; EBRT, external beam radiotherapy; HDRB, high dose rate brachytherapy; Gy, Gray.
Bolded values are considered statistically signiﬁcant.
a Model 1 co-variables include treatment arm, age and pre-existing rectal symptoms, medical conditions and habits (described under Methods), and EBRT doses controlled
by HDRB; Model 2 also includes HDRB controlled by EBRT; Model 3 In subjects receiving EBRT only this model includes% of rectal volume receiving > 60 Gy (continuous
variable).
b Endpoints: CTC = CTC proctopathy scoreP 1; BleedingP 1 = grade 1 (occult), grade 2 (>2/week), grade 3 (daily), grade 4 (gross haemorrhaging) [Lent Soma scale];
Urgency & tenesmusP 1 = grade 1 (occasional), grade 2 (intermittent), grade 3 (persistent), grade 4 (refractory) [Lent Soma scale]; FrequencyP 1 = grade 1 (2–4/day), grade
2 (5–8/day), grade 3 (>8/day), grade 4 (uncontrolled diarrhoea) [Lent Soma scale]; IncontinenceP 1 = score 1 (a little), 2 (quite a bit), 3 (very much) [IPSS Question 11: ‘‘Have
you had any unintentional release (leakage) of stools?’’].
c Percentage of rectal volume receiving greater than 60 Gy (continuous variable).
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caused a ‘‘reduction’’ in all three urinary endpoints at the end of
radiotherapy but the magnitude of this reduction was less than
for the dysfunctional rectal symptoms studied. However like rectal
symptoms, reduced dysfunctional urinary symptoms at the end of
radiotherapy in men with delayed HDRB boosts did not translate
into reduced symptom levels at later time points (Web Appendix
Fig. 1b).
No pre-treatment variable was found to inﬂuence the severity
of treatment- related urinary symptoms.
Discussion
Our data provide conﬁrmation that the use of 12 months of
adjuvant leuprorelin does not increase the dysfunctional rectal
and urinary symptoms that follow short term (6 months) neo-
adjuvant leuprorelin and radiotherapy. While this observation is
to be expected, the ﬁnding that 18 months of zoledronic acid does
not cause persistent increases in rectal and urinary symptoms
either, regardless of whether 12 months adjuvant leuprorelin is
also prescribed or not, is a new and potentially important one.Our study has also shown that modest dose escalation using
external beams alone was achieved without increased adverse con-
sequences, but that the use of a HDRB boost has produced pro-
longed urinary dysfunctional symptoms. Taken together these
ﬁndings mean that if oncological outcomes are shown to be im-
proved by 12 months of adjuvant AS and/or 18 months Z when
the 2014 main oncologic endpoints analyses of the RADAR trial
are performed, then these gains will have been achieved at a mod-
est cost due to increases in radiotherapy induced morbidity. Of
course, it must be remembered that other types of morbidity can
follow the use of adjuvant AS (e.g. fractures, sexual dysfunction,
hot ﬂushes and other detrimental quality of life issues) which
could adversely inﬂuence the cost-beneﬁt ratio, and these will be
reported separately this year [21,22].
Some readers will wonder why our data suggest that it is possi-
ble to increase prescribed dose to the prostate and seminal vesicles
from 66 to 74 Gy without increasing rectal or urinary dysfunction.
There are several reasons for this. The dose escalation programme
was accompanied by stringent ﬁeld set up stipulations [20]. This
means that as dose increased on the programme, the ﬁelds used
were not only better collimated (i.e. more conformal) but were
Table 3
Dysfunctional urinary symptoms: comparisons of the trial arms, radiation doses and techniques.
Timing Modela Variable Endpointb
IPSS PR25 Weak Stream Dysuria
Co-eff p-Value Co-eff p-Value OR p-Value OR p-Value
End XRT Model 1 STAS 0 – 0 – 1 – 1 –
STAS + Z 0.474 0.531 –0.780 0.634 0.98 0.909 0.96 0.809
ITAS 0.038 0.960 –0.525 0.746 0.97 0.895 1.05 0.783
ITAS + Z 0.207 0.782 –0.164 0.919 1.12 0.570 1.38 0.080
HDRB 0 – 0 – 1 – 1 –
66 Gy 3.511 <0.001 4.136 0.046 2.04 0.006 1.00 0.998
70 Gy 2.440 <0.001 4.932 0.001 1.61 0.019 1.21 0.269
74 Gy 4.027 <0.001 6.978 <0.001 1.83 0.007 2.09 <0.001
Model 2 EBRT 0 – 0 – 1 – 1 –
HDRB –3.087 <0.001 –5.432 <0.001 0.58 0.003 0.72 0.038
18 months Model 1 STAS 0 – 0 – 1 – 1 –
STAS + Z –0.272 0.625 –1.298 0.330 0.84 0.654 0.99 0.968
ITAS 1.231 0.026 2.669 0.044 0.98 0.948 1.01 0.973
ITAS + Z 1.849 0.001 4.744 <0.001 1.33 0.409 1.26 0.403
HDRB 0 – 0 – 1 – 1 –
66 Gy –2.479 <0.001 –6.891 <0.001 0.13 0.006 0.11 <0.001
70 Gy –2.614 <0.001 –6.688 <0.001 0.54 0.036 0.16 <0.001
74 Gy –2.610 <0.001 –7.315 <0.001 0.46 0.030 0.17 <0.001
Model 2 EBRT 0 – 0 – 1 – 1 –
HDRB 2.592 <0.001 6.914 <0.001 2.26 0.003 6.40 <0.001
36 months Model 1 STAS 0 – 0 – 1 – 1 –
STAS + Z 0.045 0.938 0.158 0.907 0.80 0.594 1.33 0.408
ITAS 0.500 0.387 –0.143 0.914 1.22 0.597 1.15 0.678
ITAS + Z –0.077 0.891 0.440 0.735 0.99 0.973 0.43 0.034
HDRB 0 – 0 – 1 – 1 -
66 Gy –0.006 0.994 –2.565 0.120 1.05 0.910 0.10 <0.001
70 Gy –1.353 0.010 –3.172 0.009 0.67 0.260 0.22 <0.001
74 Gy –0.885 0.139 –3.646 0.008 0.96 0.922 0.28 <0.001
Model 2 EBRT 0 – 0 – 1 – 1 –
HDRB 0.995 0.039 3.215 0.004 1.23 0.498 4.64 <0.001
Abbreviations: Coeff, regression coefﬁcient; OR, odds ratio; STAS, short term (6 months) androgen suppression; ITAS, intermediate term (18 months) androgen suppression; Z,
zoledronic acid; XRT, radiotherapy; EBRT, external beam radiotherapy; HDRB, high dose rate brachytherapy; Gy, Gray.
a Model 1 co-variables include treatment arm, age and pre-existing urinary symptoms, medical conditions and habits (described under ‘‘Methods’’), and EBRT doses
controlled by HBRT; Model 2 also includes HDRB controlled by EBRT.
b Endpoints: IPSS = International Prostate Symptom Score (continuous variable); PR25 = EORTC QLQ-PR25 urinary domain score (continuous variable); Weak-
streamP 4 = 4 (more than half the time), 5 (almost always) [IPSS Question 5: ‘‘How often have you had a weak urinary stream?’’]; DysuriaP 1 = grade 1 (occasional and
mild), grade 2 (intermittent and tolerable), grade 3 (persistent and intense), grade 4 (refractory and excruciating); [Lent Soma Scale].
190 Rectal and urinary dysfunctionmore consistently positioned (i.e. they covered a more consistent
volume). Moreover the use of higher prescribed doses encouraged
greater ﬁeld size reductions during treatment. These factors may
help to explain why prescribed dose did not correlate with rectal
symptom levels but the percentage of rectum receiving 60 Gy
did. Studies are on-going to determine whether other dosimetric
parameters will predict dysfunctional symptoms more accurately.
Our study also provides additional conﬁrmation that some dys-
functional rectal symptoms correlate with volume irradiated in a
different way to others [30,31]. The symptom clusters that are col-
lectively recognised as radiation proctopathy are thought to have
their origins in several different patho-physiological processes
[32–34]. It is not surprising therefore that symptoms related to
inﬂammatory processes and neuro-muscular dysfunction [35],
such as urgency and increased stool frequency, correlate best with
the size of rectal volume irradiated to high doses when inﬂamma-
tory processes are at their height at the end of radiotherapy. On the
other hand symptoms related to epithelial injury, such as bleeding
which is often associated with mucosal atrophy and telangiectasia,
correlate best with volume irradiated to high dose at later time
points when atrophy and telangiectasia have had the opportunity
to develop. Unfortunately there are many reasons why relation-
ships between rectal volumes irradiated, rectal pathology and rec-
tal physiology are difﬁcult to quantify. These include the fact that
rectal symptoms can have many different patho-physiological ori-
gins other than radiation induced proctopathy. Secondly the actualvolumes of rectum that have received high doses are imprecisely
known. For example in a small but detailed study, Hatton et al.
found that dose volume histograms (DVHs) derived at the time
of planning were poorly reproduced by cone beam derived DVHs
during treatment itself [36]. Thirdly it must be remembered that
direct radiation effects on the anal canal and indirect effects on
the small bowel and colon must also be considered. Irrespective
of these difﬁculties, however, it is reassurring that the use of a
HDRB boost to achieve dose escalation did not increase rectal
symptoms in this trial.
It is disappointing that HDRB boosts produced greater urinary
symptom levels at 18 and 36 months in this trial than external
beam dose escalation without a HDRB boost. A review of clinical
records is now underway to determine whether the increase in
dysfunctional urinary symptoms (especially dysuria) seen in men
treated with a HDRB boost can be attributed to strictures. If this
is the case then the precise site of stricturing will be important
in determining how their rate can be substantially reduced. For
example at the Peter McCallum Institute in Melbourne, Australia,
a similar boost regimen has been used and strictures were found
to occur in 11% of cases after 6 years follow up [37]. Most of these
occurred in the bulbous urethra which should have received far
lower doses than in the prostatic urethra where the maximum
dose permitted was 120% of the reference dose. This raises two
possibilities, ﬁrstly that the catheters may have migrated down-
wards after their insertion, and secondly that the bulbous urethra
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thra. If this is true then it is possible that the administration of
radiation immediately after the catheters have been inserted and
their positions veriﬁed, as practised in Offenbach, Germany [38]
could induce less morbidity.
The major limitation of our ﬁndings is that the external radio-
therapy delivered in the trial occurred before IGRT and IMRT be-
came widely available in Australia and New Zealand. IGRT in
particular could have produced a marked reduction in rectal dys-
function [39]. Another limitation is that although radiation dosage
was evenly balanced across the trial arms the allocation process
was driven by stratiﬁcation rather than by randomisation per se.
This means that selection biases could have inﬂuenced outcomes.
For example one bias that was recognised at the beginning of the
trial was the selection of men with larger more aggressive tumours
for dose escalation using the HDRB boost (as clearly shown in Ta-
ble 1). Although our analyses were adjusted for T stage and Glea-
son score it is possible that the greater overall volume irradiated
in subjects with these large tumours could have contributed to
the increased urinary dysfunction seen in those receiving the HDRB
boost.
In summary we have found that an additional 12 months AS
and 18 months Z does not cause additional rectal and urinary dys-
function when used in conjunction with 6 months neo-adjuvant AS
and radiotherapy. However the use of a HDRB boost to achieve
dose escalation has increased urinary dysfunction.Role of funding source
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